Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
N/A
1(33.3%)
3Total
Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04187443Phase 1Recruiting

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

Role: collaborator

NCT04026282Not ApplicableUnknown

To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment

Role: collaborator

NCT03175497Phase 1Completed

Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors

Role: collaborator

All 3 trials loaded